Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Operating Activities:
Net loss	$ (19,321)	$ (110,795)
Adjustments to reconcile net loss to net cash used in operating activities:
(Gain) loss from discontinued operations	(1,166)	51,934
Non-cash revenue reserve	201	172
Depreciation and amortization	547	965
Stock-based compensation expense	3,499	5,625
Loss on extinguishment of convertible notes	0	242
Amortization of debt discount and non-cash interest	694	4,753
Loss on disposal of property and equipment	320	0
Impairment of property and equipment	545	0
Gain on investment in Enumera Molecular, Inc.	(5,731)	0
Change in fair value of derivative liability	0	(17,977)
Change in fair value of warrant liability	(13,402)	2,496
Changes in operating assets and liabilities:
Income tax receivable	(817)	0
Prepaid expenses and other current assets	(904)	(4,888)
Other assets	0	22
Accounts payable	(4,434)	1,683
Accrued expenses and other liabilities	(4,486)	7,041
Other long-term liabilities	(958)	6,591
Net cash used in operating activities - continuing operations	(45,413)	(52,136)
Net cash provided by (used in) operating activities - discontinued operations	1,819	(32,114)
Net cash used in operating activities	(43,594)	(84,250)
Investing Activities:
Purchases of property and equipment	(556)	(853)
Net cash used in investing activities - continuing operations	(556)	(853)
Net cash used in investing activities - discontinued operations	0	(168)
Net cash used in investing activities	(556)	(1,021)
Financing Activities:
Proceeds from issuance of common stock, net	4,794	23,377
Proceeds from issuance of common stock warrants	0	39,430
Proceeds from issuance of common stock under employee stock purchase plan	89	0
Payment of deferred offering costs	0	(50)
Payments for financing of insurance premiums	(612)	(2,680)
Principal payments on mortgages payable	0	(35)
Principal payments on capital lease obligations	(12)	(179)
Net cash provided by financing activities - continuing operations	4,259	59,863
Net cash used in financing activities - discontinued operations	0	(121)
Net cash provided by financing activities	4,259	59,742
Net decrease in cash and cash equivalents	(39,891)	(25,529)
Cash and cash equivalents at beginning of period	88,397	91,520
Cash and cash equivalents at end of period	48,506	65,991
Supplemental disclosure of cash flow information:
Cash paid for interest	4,811	3,068
Cash paid for income taxes	17	46
Supplemental schedule of non-cash investing and financing activities:
Lease assets obtained in exchange for operating lease liabilities	2,922	0
Investment in Enumera Molecular, Inc. in exchange for assets	6,000	0
Purchases of property and equipment in accounts payable	40	135
Conversion of convertible note	0	2,069
Issuance of common stock upon conversion of interest	0	3,627
Equity offering costs incurred but not paid	0	2,150
Debt offering costs incurred but not paid	$ 0	$ 62